SAB Biotherapeutics, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Breakthrough T1D awarded a grant to support PRISE-hATG, a clinical study led by Dr. Michael J. Haller at the University of Florida evaluating SAB-142 in Stage 3 Type 1 Diabetes patients 100 days to 2 years post-diagnosis. SAB Biotherapeutics will co-fund the study, which is designed to assess whether SAB-142 can preserve beta cell function and modulate immune responses in patients with residual beta cell function, complementing the ongoing Phase 2b SAFEGUARD trial. No specific grant amount or SAB contribution dollar figure is disclosed in the filing.
Why this rating
Clinical trial expansion supports lead program; no funding amount disclosed; moderate positive signal but modest relative to $76.7M market cap—routine development news.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.